Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Repeated measures design

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11 result(s) found for: Repeated measures design. Displaying page 1 of 1.
    EudraCT Number: 2006-001232-42 Sponsor Protocol Number: RGHT000270 Start Date*: 2006-06-14
    Sponsor Name:Royal Group of Hospitals Trust
    Full Title: The Pharmacogenetics of Aspirin Resistance
    Medical condition: Aspirin resistance: Vascular diseases are common problems and aspirin is used as an anti-platelet drug to prevent thrombosis. However, aspirin's anti-platelet effect may not be uniform in all patie...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-004919-11 Sponsor Protocol Number: FLAIR-i Start Date*: 2022-05-03
    Sponsor Name:Donders Institute for Brain, Cognition and Behaviour, Radboud University
    Full Title: The effect of colchicine on Food-reLAted effort-based decision making in brain and behavIouR in overweight and obesity: the FLAIR-i study.
    Medical condition: Low-grade inflammation in obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    24.1 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003052-36 Sponsor Protocol Number: 19067 Start Date*: 2020-01-06
    Sponsor Name:The University of Nottingham
    Full Title: Triple Modality Functional Magnetic Resonance Lung Imaging in Cystic Fibrosis and Non-CF Bronchiectasis
    Medical condition: Cystic fibrosis (CF) Non-CF Bronchiectasis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10038738 - Respiratory, thoracic and mediastinal disorders 10006445 Bronchiectasis PT
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2010-022307-22 Sponsor Protocol Number: BergenPsychosisProject2 Start Date*: 2011-04-14
    Sponsor Name:Haukeland University Hospital, Division of Psychiatry
    Full Title: The Bergen Psychosis Project 2
    Medical condition: Patients with schizophrenia and related non-affective psychotic disorders, corresponding to ICD-10 diagnoses F10.5-19.5, and F20-29.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003935-12 Sponsor Protocol Number: ATRiUM Start Date*: 2019-06-13
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
    Full Title: ATRiUM: A phase 1 trial to assess the safety, tolerability, pharmacokinetics and preliminary antitumor activity of ascending doses of combined therapy with ATR inhibitor AZD6738 and gemcitabine, Us...
    Medical condition: Locally advanced or metastatic solid tumour.
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10065143 Malignant solid tumour LLT
    20.0 100000004864 10049280 Solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-005374-57 Sponsor Protocol Number: Calcimimetics Start Date*: 2013-02-15
    Sponsor Name:Department of Breast and Endocrine Surgery, Karolinska University Hospital
    Full Title: Primary hyperparathyroidism: Short-term calcimimetics treatment – Relevance for parathyroid surgery decisions?
    Medical condition: Primary hyperparathyroidism (PHPT) is a common disease, characterized by a high-normal calcium concentration and an inappropriately increased parathyroid hormone (PTH) level
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004860 10036693 Primary hyperparathyroidism LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005263-16 Sponsor Protocol Number: NSC15001 Start Date*: 2016-07-11
    Sponsor Name:Pharmatrophix Inc
    Full Title: A 6-months prospective, multi-center, double-blind, placebo-controlled, randomized, adaptive-trial-design study to evaluate safety, tolerability and exploratory endpoints of either placebo or two d...
    Medical condition: Mild to moderate Alzheimer's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    20.0 100000004852 10066571 Progression of Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) DE (Completed) SE (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-006257-40 Sponsor Protocol Number: ACI-24-0701 Start Date*: 2009-12-09
    Sponsor Name:AC Immune SA
    Full Title: A Phase I/II Double-Blind, Randomised, Placebo-Controlled, Adaptive Design Study of the Safety, Tolerability, Immunogenicity and Efficacy of ACI-24 in Patients with Mild to Moderate Alzheimer's Dis...
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-002893-11 Sponsor Protocol Number: PASIPHAE Start Date*: 2017-08-14
    Sponsor Name:Karolinska University Hospital
    Full Title: A phase 2, international, multicenter, open-labeled, randomized trial of PAlbociclib and fulvestrant vs. Standard oral capecitabine In Patients with Hormone receptor positive/HER2 negative Advanced...
    Medical condition: Hormone receptor positive/HER2 negative advanced breast cancer with endocrine resistance
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Prematurely Ended) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-000567-26 Sponsor Protocol Number: 2010-021883-14 Start Date*: 2013-01-31
    Sponsor Name:Radboud University Medical Centre Nijmegen
    Full Title: A randomized double-blind, placebo-controlled study of risperidone in the treatment of DSM-IV-TR conduct disorder in children and adolescents.
    Medical condition: Conduct Disorder DSM-IV-TR; 312.8x¸ APA, 2000
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10064478 Conduct disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) DE (Ongoing) GB (GB - no longer in EU/EEA) ES (Ongoing) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021884-34 Sponsor Protocol Number: PERS3 Start Date*: 2013-01-24
    Sponsor Name:Radboud University Medical Centre Nijmegen
    Full Title: Relapse prevention in children and adolescents with DSM-IV Conduct Disorder treated with Risperidone: a Randomized Double blind, Placebo-Controlled, Discontinuation Study.
    Medical condition: Conduct Disorder DSM-IV-TR; 312.8x, APA 2000
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10064478 Conduct disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) DE (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 07 01:21:39 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA